Journal List > J Korean Soc Spine Surg > v.24(1) > 1076157

Ahn, Shin, and Kim: Analgesic Effects of Antiosteoporotic Drugs

Abstract

Study design

Literature review.

Objectives

To propose possible mechanisms of osteoporotic back pain and its management with antiosteoporotic drugs.

Summary of Literature Review

No general conclusion has yet been reached regarding whether osteoporosis without fractures can cause pain. Instead, only treatments for back pain without osteoporotic spine fractures have been reviewed in the previous literature. Although key studies of antiosteoporotic drugs have not investigated their analgesic efficacy, plausible mechanisms have been suggested.

Materials and Methods

The analgesic effects of antiosteoporotic agents available in Korea were reviewed.

Results

Rather than the long-term use of conventional analgesics or narcotics, antiosteoporotic drugs would be more beneficial because they can enhance bone strength and have fewer side effects. Both anabolic and antiresorptive agents available in Korea have been proven to have an analgesic effect against osteoporotic back pain, with or without fractures. Anabolic agents depend on skeletal effects. Among antiresorptive agents, bisphosphonates have both skeletal and extraskeletal mechanisms for analgesia. Calcitonin and selective estrogen receptor modulators mostly depend on extraskeletal effects. The order of analgesic strength for osteoporotic back pain is teriparatide > bisphosphonate > calcitonin. This implies that the analgesic effect of antiosteoporotic drugs primarily depends on their skeletal effects rather than on their extraskeletal effects. Moreover, because non-fracture osteoporotic pain has been recognized only in the spine, where fractures can occur without a sensible injury, pain may arise from undiscovered spine fractures.

Conclusions

Antiosteoporotic drugs ameliorate osteoporotic back pain. Their analgesic strength is proportional to their fracture prevention efficacy.

REFERENCES

1. Muraki S, Oka H, Akune T, et al. Prevalence of radiographic knee osteoarthritis and its association with knee pain in the elderly of Japanese population-based cohorts: the ROAD study. Osteoarthritis Cartilage. 2009; 17:1137–43.
crossref
2. Edwards RR, Fillingim RB, Ness TJ. Age-related differences in endogenous pain modulation: a comparison of diffuse noxious inhibitory controls in healthy older and younger adults. Pain. 2003; 101:155–65.
crossref
3. Cole LJ, Farrell MJ, Gibson SJ, et al. Age-related differences in pain sensitivity and regional brain activity evoked by noxious pressure. Neurobiol Aging. 2010; 31:494–503.
crossref
4. Jimenez-Andrade JM, Mantyh WG, Bloom AP, et al. The effect of aging on the density of the sensory nerve fiber in-nervation of bone and acute skeletal pain. Neurobiol Aging. 2012; 33:921–32.
crossref
5. Gaus S, Moriwaki K, Suyama H, et al. Capsaicin treatment inhibits osteopenia and heat hyperalgesia induced by chronic constriction injury to the sciatic nerve in rats. Hiroshima J Med Sci. 2003; 52:43–51.
6. Nagae M, Hiraga T, Wakabayashi H, et al. Osteoclasts play a part in pain due to the inflammation adjacent to bone. Bone. 2006; 39:1107–15.
crossref
7. Rogers MJ, Crockett JC, Coxon FP, et al. Biochemical and molecular mechanisms of action of bisphosphonates. Bone. 2011; 49:34–41.
crossref
8. Iwamoto J, Takeda T, Sato Y, et al. Effects of alendronate on metacarpal and lumbar bone mineral density, bone resorption, and chronic back pain in postmenopausal women with osteoporosis. Clin Rheumatol. 2004; 23:383–9.
9. Corrado A, Santoro N, Cantatore FP. Extraskeletal effects of bisphosphonates. Joint Bone Spine. 2007; 74:32–8.
crossref
10. Ceponis A, Waris E, Monkkonen J, et al. Effects of low-dose, noncytotoxic, intraarticular liposomal clodronate on development of erosions and proteoglycan loss in estab-lished antigen-induced arthritis in rabbits. Arthritis Rheum. 2001; 44:1908–16.
11. Kim S, Seiryu M, Okada S, et al. Analgesic effects of the non-nitrogen-containing bisphosphonates etidronate and clodronate, independent of antiresorptive effects on bone. Eur J Pharmacol. 2013; 699:14–22.
crossref
12. Fujita T, Ohue M, Fujii Y, et al. Comparison of the analgesic effects of bisphosphonates: etidronate, alendronate and risedronate by electroalgometry utilizing the fall of skin impedance. J Bone Miner Metab. 2009; 27:234–9.
crossref
13. Pappagallo M, Breuer B, Lin HM, et al. A pilot trial of intravenous pamidronate for chronic low back pain. Pain. 2014; 155:108–17.
crossref
14. Pappagallo M, Breuer B, Schneider A, et al. Treatment of chronic mechanical spinal pain with intravenous pamidronate: a review of medical records. J Pain Symptom Manage. 2003; 26:678–83.
crossref
15. Ohtori S, Akazawa T, Murata Y, et al. Risedronate de-creases bone resorption and improves low back pain in postmenopausal osteoporosis patients without vertebral fractures. J Clin Neurosci. 2010; 17:209–13.
crossref
16. Bonabello A, Galmozzi MR, Canaparo R, et al. Long-term analgesic effect of clodronate in rodents. Bone. 2003; 33:567–74.
crossref
17. Iolascon G, Gimigliano F, Malavolta N, et al. Effectiveness of teriparatide treatment on back pain-related functional limitations in individuals affected by severe osteoporosis: a prospective pilot study. Clin Cases Miner Bone Metab. 2012; 9:161–5.
18. Ritchie RO. How does human bone resist fracture? Ann N Y Acad Sci. 2010; 1192:72–80.
crossref
19. Hadji P, Zanchetta JR, Russo L, et al. The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures. Osteoporos Int. 2012; 23:2141–50.
crossref
20. Dobolyi A, Ueda H, Uchida H, et al. Anatomical and phys-iological evidence for involvement of tuberoinfundibular peptide of 39 residues in nociception. Proc Natl Acad Sci U S A. 2002; 99:1651–6.
crossref
21. Chhabra H, Malhotra R, Marwah S, et al. An observational study to assess back pain in patients with severe osteoporosis treated with teriparatide versus antiresorptives: An Indian subpopulation analysis. Indian J Endocrinol Metab. 2015; 19:483–90.
22. Fischer JA, Tobler PH, Kaufmann M, et al. Calcitonin: regional distribution of the hormone and its binding sites in the human brain and pituitary. Proc Natl Acad Sci U S A. 1981; 78:7801–5.
crossref
23. Lyritis GP, Ioannidis GV, Karachalios T, et al. Analgesic effect of salmon calcitonin suppositories in patients with acute pain due to recent osteoporotic vertebral crush fractures: a prospective double-blind, randomized, placebo-controlled clinical study. Clin J Pain. 1999; 15:284–9.
crossref
24. Overman RA, Borse M, Gourlay ML. Salmon calcitonin use and associated cancer risk. Ann Pharmacother. 2013; 47:1675–84.
crossref
25. Musgrave DS, Vogt MT, Nevitt MC, et al. Back problems among postmenopausal women taking estrogen replacement therapy: the study of osteoporotic fractures. Spine (Phila Pa 1976). 2001; 26:1606–12.
26. Scharla S, Oertel H, Helsberg K, et al. Skeletal pain in postmenopausal women with osteoporosis: prevalence and course during raloxifene treatment in a prospective observational study of 6 months duration. Curr Med Res Opin. 2006; 22:2393–402.
crossref
27. Gennari C, Chierichetti MS, Gonnelli S, et al. Migraine prophylaxis with salmon calcitonin: a cross-over double-blind, placebo-controlled study. Headache. 1986; 26:13–6.
crossref
28. Micieli G, Cavallini A, Martignoni E, et al. Effectiveness of salmon calcitonin nasal spray preparation in migraine treatment. Headache. 1988; 28:196–200.
crossref
29. Iwamoto J, Makita K, Sato Y, et al. Alendronate is more effective than elcatonin in improving pain and quality of life in postmenopausal women with osteoporosis. Osteoporos Int. 2011; 22:2735–42.
crossref
30. Songpatanasilp T, Mumtaz M, Chhabra H, et al. Back pain in patients with severe osteoporosis on teriparatide or anti-resorptives: a prospective observational study in a multieth-nic population. Singapore Med J. 2014; 55:493–501.
crossref
TOOLS
Similar articles